#### **RBM WG MIP Annual Meeting**

13 February 2018 Maputo, Mozambique



#### **Matthew Chico**

Assistant Professor

London School of Hygiene & Tropical Medicine

Email: matthew.chico@lshtm.ac.uk

Mobile: +44 794 844 4456 | Office: +44 207 927 2841



# IPTp-SP versus IPTp-DP





Figure 2: Forest plot of the efficacy of IPTp-DP vs IPTp-SP for the prevention of malaria in pregnancy in sub-Saharan Africa


Desai, Meghna, et al. "Prevention of malaria in pregnancy." The Lancet infectious diseases (2018).




# Sulphonamide and STIs/RTIs




#### Sulphonamide curative of Gonorrhoea



Sulphonamide curative of *Gardnerella* vaginalis (common BV-associated bacteria)




#### Sulphisoxazole curative of chlamydia



**Sulphonamide curative of trichomonas** 

# Burden of malaria and curable STIs/RTIs in pregnancy East and Southern Africa


Pooled prevalence of malaria and STIs/RTIs in pregnancy with highest and lowest point estimates



Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of Malaria and Sexually Transmitted and Reproductive Tract Infections in Pregnancy in Sub-Saharan Africa: A Systematic Review. *JAMA. May 16 2012;307(19):2079-2086*.

# Burden of malaria and curable STIs/RTIs in pregnancy West and Central Africa

Pooled prevalence of malaria and STIs/RTIs in pregnancy with highest and lowest point estimates



Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of Malaria and Sexually Transmitted and Reproductive Tract Infections in Pregnancy in Sub-Saharan Africa: A Systematic Review. *JAMA. May 16 2012;307(19):2079-2086.* 

#### Leading candidates to replace SP


**Option 1**: Dihydroartemisinin-piperaquine (DP) alone

**Option 2**: Combination therapy that is protective against 'malaria and curable STIs/RTIs', eg.

- 1. DP plus azithromycin (Kenya, Tanzania, Malawi)
- Piperaquine plus azithromycin (PNG)
- 3. SP plus metronidazole (Zambia)
- 4. DP plus metronidazole (Zambia)

# Observational cohort study of IPTp-SP: malaria and curable STIs/RTIs






Chaponda EB, Chico RM, Bruce J, et al. Malarial Infection and Curable Sexually Transmitted and Reproductive Tract Infections among Pregnant Women in a Rural District of Zambia. *American Journal of Tropical Medicine and Hygiene*, Volume 95, Issue 5, Nov 2016, pp. 1069-1076



# Prevalence of PCR-diagnosed malaria and individual curable STIs/RTIs among pregnant women at antenatal care facilities in Nchelenge District, Zambia (2013-14)



Chaponda EB, Chico RM, Bruce J, et al. Malarial Infection and Curable Sexually Transmitted and Reproductive Tract Infections among Pregnant Women in a Rural District of Zambia. *American Journal of Tropical Medicine and Hygiene*, Volume 95, Issue 5, Nov 2016, pp. 1069-1076



#### IPTp-SP: malaria and non-malarial effects

#### Categories of maternal infection and exposure to doses 0 – 1 versus <u>></u> 2 doses of IPTp-SP among women with adverse birth outcomes

Adverse birth outcomes	0-1 dose IPTp-SP		≥ 2 doses IPTp-SP		Crude	05% 61	Adjusted	05% 61						
Categories of infection	No. women	No. outcomes	No. women	No. outcomes	OR	95% CI	OR	95% CI						
Any adverse outcome														
Malaria only	20	13	129	41	0.25	0.09, 0.88	0.24	0.09, 0.66						
NG and/or CT only	6	4	14	2	0.08	0.01, 0.80	0.08	0.01, 0.64						
No identified infection	26	12	97	22	0.34	0.14, 0.85	0.27	0.11, 0.68						
Low birth weight														
No identified infection	26	8	97	13	0.35	0.13, 0.96	0.24	0.08, 0.68						
Preterm delivery														
Malaria only	20	10	129	21	0.19	0.07, 0.53	0.19	0.07, 0.53						
Malaria and TV and/or BV	38	14	182	37	0.44	0.21, 0.93	0.45	0.21, 0.97						
NG and/or CT only	6	4	14	2	0.08	0.01, 0.80	0.07	0.01, 0.73						
No identified infection	26	10	97	12	0.23	0.08, 0.61	0.20	0.07, 0.54						

NG = Neisseria gonorrhoeae; CT = Chlamydia trachomatis; TV = Trichomonas vaginalis; BV = Bacterial vaginosis

Chico RM, Chaponda EB, Ariti C, Chandramohan D. Sulfadoxine-pyrimethamine exhibits dose-response protection against adverse birth outcomes related to sexually transmitted and reproductive tract infections. *Clinical Infectious Diseases* (2 March, 2017) <a href="https://doi.org/10.1093/cid/cix026">https://doi.org/10.1093/cid/cix026</a>





#### **Study Interventions**

5,436 pregnant women (1,812 per group)

**Group 1:** IPTp-SP\* plus metronidazole (MTZ) placebo

**Group 2:** IPTp-SP plus MTZ\*

**Group 3:** IPTp-DP plus MTZ\*

\* Baxy Pharmaceuticals of Ndola, Zambia samples quality tested in LSHTM laboratories





#### **Study Population**

HIV-negative pregnant women (all gravidae) between 16-28 weeks gestation assessed by ultrasound dating who have not yet started IPTp during the current pregnancy.





#### **Primary outcome**

Any adverse pregnancy outcome

Composite of foetal loss (spontaneous abortion or stillbirth), or singleton live births born small for gestational age (SGA), or low birth weight (LBW; <2.5kg), or preterm delivery (<37 weeks), or neonatal death





#### Secondary outcomes

- (1) single outcomes of the composite pregnancy outcome
- (2) incidence of clinical malaria
- (3) incidence of curable STIs/RTIs



### Sub-studies

**Sub-study 1**: Effect of treatment on vaginal and intestinal microbiome and maternal cytokines (London, UK)

Objective: To characterise the effect of treatment across trial arms on the vaginal and intestinal microbiota communities, vaginal and intestinal bacterial loads and soluble markers of inflammation.

# Sub-studies

Sub-study 2: In vitro testing of sulphadoxine and other antimicrobial agents (Ndola, Zambia)

Objective: To measure the drug sensitivity of several pathogens implicated with WHO syndromes of vaginal discharge, lower abdominal pain, or genital ulcers in the presence of sulphadoxine and other antimicrobial agents.

# **Gantt chart**



Activity	Pre-	Year 1		Year 2		Year 3		Year 4	
	award	Prep	Recruit	ment and follow-up				Close	
Engage local, national and int'l stakeholders									
Prepare protocol and related documents									
Obtain ethics and regulatory approval									
Develop electronic data capture system									
Convene DMEC and TSC									
Deliver investigational products									
Conduct SOP and GCP training / review									
Enrol and follow-up participants									
Conduct trial audit or monitoring visit									
Conduct interim analysis									
End-line data analysis									





# Investigators

#### **Chief Investigators**

- Matthew Chico
- Daniel Chandramohan

#### **Local Principal Investigator - Zambia**

Mike Chaponda

#### Co-Investigators – Zambia

- Modest Mulenga
- Sebastian Hachizovu
- Enesia Banda Chaponda Ngulube

#### **Co-Investigators – United Kingdom**

- Elizabeth Allen
- Philippe Mayaud
- Suzanna Francis
- Nigel Klein
- David MacIntyre
- Antonieta Medina-Lara





Imperial College London





# Thanks to ...











